Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone

Annals of the Rheumatic Diseases

Volumn 75, Issue 9, 2016, Pages 1714-1721

  Cui, Zhuang ^a,b   Crane, Janet ^a   Xie, Hui ^a   Jin, Xin ^a   Zhen, Gehua ^a   Li, Changjun ^a   Xie, Liang ^a   Wang, Long ^a   Bian, Qin ^a   Qiu, Tao ^a   Wan, Mei ^a   Xie, Min ^c   Ding, Sheng ^c   Yu, Bin ^b   Cao, Xu ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arthritis; Osteoarthritis; Treatment

Indexed keywords

AGGRECAN; AGGRECANASE 2; COLLAGEN TYPE 10; COLLAGEN TYPE 2; COLLAGENASE 3; HALOFUGINONE; LUBRICIN; MEMBRANE PROTEIN; PROTEOGLYCAN; RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRABECULAR PATTERN FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CRUCIATE LIGAMENT; ARTICLE; ARTICULAR CARTILAGE; BONE; BONE MASS; BONE MICROARCHITECTURE; BONE REMODELING; C57BL 6 MOUSE; CALCIFICATION; CARTILAGE DEGENERATION; COMPUTED TOMOGRAPHY MICROANGIOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LEWIS RAT; MALE; MANKIN CRITERIA; MICRO-COMPUTED TOMOGRAPHY; MICROANGIOGRAPHY; MOUSE; MUSCULOSKELETAL DISEASE ASSESSMENT; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OPTIMAL DRUG DOSE; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOSCLEROSIS; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; SIGNAL TRANSDUCTION; SUBCHONDRAL BONE; TH17 CELL; TIBIA; WESTERN BLOTTING; WILD TYPE MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; OSTEOCLAST; PREVENTION AND CONTROL; RANDOMIZATION; SURGERY;

ANIMALS; ANTERIOR CRUCIATE LIGAMENT; BONE AND BONES; BONE REMODELING; BONE RESORPTION; CARTILAGE, ARTICULAR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MALE; MICE; MICE, INBRED C57BL; OSTEOARTHRITIS; OSTEOCLASTS; PIPERIDINES; QUINAZOLINONES; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; TRANSFORMING GROWTH FACTOR BETA;

EID: 84984963166     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207923     Document Type: Article

References (61)

1. Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002; 14: 573-7.
2. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Athritis Rheum 2008; 58: 26-35.
3. Berenbaum F. Osteoarthritis year 2010 in review: pharmacological therapies. Osteoarthritis Cartilage 2011; 19: 361-5.
4. Hawker GA, Mian S, Bednis K, et al. Osteoarthritis year 2010 in review: non-pharmacologic therapy. Osteoarthritis Cartilage 2011; 19: 366-74.
5. van den Berg WB. Osteoarthritis year 2010 in review: pathomechanisms. Osteoarthritis Cartilage 2011; 19: 338-41.
6. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7: 33-42.
7. Madry H. The subchondral bone: a new frontier in articular cartilage repair. Knee Surg Sports Traumatol Arthrosc 2010; 18: 417-18.
8. Goldring SR. Alterations in periarticular bone and cross talk between subchondral bone and articular cartilage in osteoarthritis. Ther Adv Musculoskelet Dis 2012; 4: 249-58.
9. Roemer FW, Guermazi A, Javaid MK, et al. Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss: the MOST Study. A longitudinal multicentre study of knee osteoarthritis. Ann Rheum Dis 2009; 68: 1461-5.
10. Hunter DJ, Zhang Y, Niu J, et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Ann Rheum Dis 2006; 54: 1529-35.
11. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 2008; 67: 683-8.
12. Tanamas SK, Wluka AE, Pelletier JP, et al. Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint replacement: a longitudinal study. Rheumatology (Oxford) 2010; 49: 2413-19.
13. Kothari A, Guermazi A, Chmiel JS, et al. Within-subregion relationship between bone marrow lesions and subsequent cartilage loss in knee osteoarthritis. Arthritis Care Res 2010; 62: 198-203.
14. Lories RJ and Luyten FP. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol 2011; 7: 43-9.
15. Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat Rev Rheumatol 2012; 8: 665-73.
16. Layton MW, Goldstein SA, Goulet RW, et al. Examination of subchondral bone architecture in experimental osteoarthritis by microscopic computed axial tomography. Arthritis Rheum 1988; 31: 1400-5.
17. Madry H, van Dijk CN, Mueller-Gerbl M. The basic science of the subchondral bone. Knee Surg Sports Traumatol Arthrosc 2010; 18: 419-33.
18. Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15: 757-65.
19. Xian L, Wu X, Pang L, et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 2012; 18: 1095-101.
20. Xie H, Cui Z, Wang L, et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med 2014; 20: 1270-8.
21. Crane JL, Zhao L, Frye JS, et al. IGF-1 signaling is essential for differentiation of mesenchymal stem cells for peak bone mass. Bone Res 2013; 1: 186-94.
22. Zhen G, Cao X. Targeting TGFβ signaling in subchondral bone and articular cartilage homeostasis. Trends Pharmacol Sci 2014; 35: 227-36.
23. Khorasani MS, Diko S, Hsia AW, et al. Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice. Arthritis Res Ther 2015; 17: 30.
24. Hayami T, Zhuo Y, Wesolowski GA, et al. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 2012; 50: 1250-9.
25. Cao X. Targeting osteoclast-osteoblast communication. Nat Med 2011; 17: 1344-6.
26. Zhen G, Wen C, Jia X, et al. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med 2013; 19: 704-12.
27. Suri S, Gill SE, Massena de Camin S, et al. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Ann Rheum Dis 2007; 66: 1423-8.
28. Mapp PI, Walsh DA, Bowyer J, et al. Effects of a metalloproteinase inhibitor on osteochondral angiogenesis, chondropathy and pain behavior in a rat model of osteoarthritis. Osteoarthritis Cartilage 2010; 18: 593-600.
29. Kusumbe AP, Ramasamy SK, Adams RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 2014; 507: 323-8.
30. Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998; 30: 445-50.
31. Jiang S, Zeng Q, Gettayacamin M, et al. Antimalarial activities and therapeutic properties of febrifugine analogs. Antimicrob Agents Chemother 2005; 49: 1169-76.
32. Gnainsky Y, Kushnirsky Z, Bilu G, et al. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res 2007; 328: 153-66.
33. Pines M, Snyder D, Yarkoni S, et al. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 2003; 9: 417-25.
34. Sundrud MS, Koralov SB, Feuerer M, et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 2009; 324: 1334-8.
35. Park MK, Park JS, Park EM, et al. Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis. Arthritis Rheumatol 2014; 66: 1195-207.
36. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-32.
37. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-41.
38. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-82.
39. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-52.
40. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-4.
41. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8.
42. Elkin M, Miao HQ, Nagler A, et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J 2000; 14: 2477-85.
43. Ishii H, Tanaka H, Katoh K, et al. Characterization of infiltrating T cells and Th1/Th2-type cytokines in the synovium of patients with osteoarthritis. Osteoarthritis Cartilage 2002; 10: 277-81.
44. Shen PC, Wu CL, Jou IM, et al. T helper cells promote disease progression of osteoarthritis by inducing macrophage inflammatory protein-1γ. Osteoarthritis Cartilage 2011; 19: 728-36.
45. Pritzker KP, Gay S, Jimenez SA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006; 14: 13-29.
46. Liu HP, Cao AT, Feng T, et al. TGF-β converts Th1 cells into Th17 cells through stimulation of Runx1 expression. Eur J Immunol 2015; 45: 1010-18.
47. Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-β inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol 2000; 165: 4773-7.
48. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002; 195: 1499-505.
49. Keller TL, Zocco D, Sundrud MS, et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol 2012; 8: 311-17.
50. Zhou H, Sun L, Yang XL, et al. ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase. Nature 2013; 494: 121-4.
51. Shen J, Li S, Chen D. TGF-β signaling and the development of osteoarthritis. Bone Res 2014; 2: 14002.
52. Arnoldi CC, Linderholm H, Müssbichler H. Venous engorgement and intraosseous hypertension in osteoarthritis of the hip. J Bone Joint Surg Br 1972; 54: 409-21.
53. Mapp PI, Avery PS, McWilliams DF, et al. Angiogenesis in two animal models of osteoarthritis. Osteoarthritis Cartilage 2008; 16: 61-9.
54. Cui Z, Xu C, Li X, et al. Treatment with recombinant lubricin attenuates osteoarthritis by positive feedback loop between articular cartilage and subchondral bone in ovariectomized rats. Bone 2015; 74: 37-47.
55. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237-41.
56. Liotta LA, Tryggvason K, Garbisa S, et al. Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry 1981; 20: 100-4.
57. Yurchenco PD and Schittny JC. Molecular architecture of basement membranes. FASEB J 1990; 4: 1577-90.
58. Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011; 117: 6999-7006.
59. Leiba M, Cahalon L, Shimoni A, et al. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. J Leukoc Biol 2006; 80: 399-406.
60. Pines M, Spector I. Halofuginone-the multifaceted molecule. Molecules 2015; 20: 573-94.
61. McLoon LK. Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy. Am J Physiol Heart Circ Physiol 2008; 294: H1505-7.